دورية أكاديمية
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective.
| العنوان: | Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. |
|---|---|
| المؤلفون: | Soosaipillai G; Cancer Division, University College London Hospitals, London, UK., Wu A; Cancer Division, University College London Hospitals, London, UK., Dettorre GM; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK., Diamantis N; Medical Oncology, Barts Health NHS Trust, London, UK., Chester J; Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK., Moss C; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Aguilar-Company J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, UK., Sng CC; Cancer Division, University College London Hospitals, London, UK., Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC. Hospitalet de Llobregat, Spain., Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Jones E; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Mesia R; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain., Jackson A; Clinical Trials, Velindre Cancer Centre, Cardiff, UK., Mukherjee U; Medical Oncology, Barts Health NHS Trust, London, UK., Sita-Lumsden A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Seguí E; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Ottaviani D; Cancer Division, University College London Hospitals, London, UK., Carbó A; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Benafif S; Cancer Division, University College London Hospitals, London, UK., Würstlein R; Department of Gynaecology and Obstetrics, Breast Centre and Gynaecological Cancer Centre and CCC Munich, University Hospital Munich, Munich, Germany., Carmona C; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Chopra N; Cancer Division, University College London Hospitals, London, UK., Cruz CA; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Swallow J; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK., Saoudi N; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Felip E; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain., Galazi M; Cancer Division, University College London Hospitals, London, UK., Garcia-Fructuoso I; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Lee AJX; Cancer Division, University College London Hospitals, London, UK., Newsom-Davis T; Department of Oncology and National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, UK., Wong YNS; Cancer Division, University College London Hospitals, London, UK., Sureda A; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Spain., Maluquer C; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Spain., Ruiz-Camps I; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain., Cabirta A; Department of Haematology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Prat A; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Loizidou A; Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, Novara, Italy., Ferrante D; Department of Translational Medicine, Unit of Cancer Epidemiology, CPO-Piemonte, University of Eastern Piedmont, Novara, Italy., Tabernero J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Russell B; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Van Hemelrijck M; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Dolly S; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Hulbert-Williams NJ; Professor of Behavioural Medicine, Centre for Contextual Behavioural Science, School of Psychology, University of Chester, Chritchley Building, Parkgate Road, Chester, Cheshire, CH1 4BJ, UK., Pinato DJ; Department of Surgery and Cancer, Clinical Senior Lecturer and Consultant Medical Oncologist, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK. |
| المصدر: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2021 Sep 02; Vol. 13, pp. 17588359211042224. Date of Electronic Publication: 2021 Sep 02 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Sage |
| مستخلص: | Background: Specialist palliative care team (SPCT) involvement has been shown to improve symptom control and end-of-life care for patients with cancer, but little is known as to how these have been impacted by the COVID-19 pandemic. Here, we report SPCT involvement during the first wave of the pandemic and compare outcomes for patients with cancer who received and did not receive SPCT input from multiple European cancer centres. Methods: From the OnCovid repository ( N = 1318), we analysed cancer patients aged ⩾18 diagnosed with COVID-19 between 26 February and 22 June 2020 who had complete specialist palliative care team data (SPCT+ referred; SPCT- not referred). Results: Of 555 eligible patients, 317 were male (57.1%), with a median age of 70 years (IQR 20). At COVID-19 diagnosis, 44.7% were on anti-cancer therapy and 53.3% had ⩾1 co-morbidity. Two hundred and six patients received SPCT input for symptom control (80.1%), psychological support (54.4%) and/or advance care planning (51%). SPCT+ patients had more 'Do not attempt cardio-pulmonary resuscitation' orders completed prior to (12.6% versus 3.7%) and during admission (50% versus 22.1%, p < 0.001), with more SPCT+ patients deemed suitable for treatment escalation (50% versus 22.1%, p < 0.001). SPCT involvement was associated with higher discharge rates from hospital for end-of-life care (9.7% versus 0%, p < 0.001). End-of-life anticipatory prescribing was higher in SPCT+ patients, with opioids (96.3% versus 47.1%) and benzodiazepines (82.9% versus 41.2%) being used frequently for symptom control. Conclusion: SPCT referral facilitated symptom control, emergency care and discharge planning, as well as high rates of referral for psychological support than previously reported. Our study highlighted the critical need of SPCTs for patients with cancer during the pandemic and should inform service planning for this population. Competing Interests: Conflict of interest statement: DJP received lecture fees from ViiV Healthcare and Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, and Astra Zeneca; received research funding (to institution) from MSD and BMS. AP has declared personal honoraria from Pfizer, Novartis, Roche, MSD Oncology, Eli Lilly, and Daiichi Sankyo; travel, accommodations, and expenses paid by Daiichi Sankyo; research funding from Roche and Novartis; and consulting/advisory role for NanoString Technologies, Amgen, Roche, Novartis, Pfizer and Bristol-Myers Squibb. TND has declared consulting/advisory role for Amgen, Bayer, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Otsuka, Pfizer, Roche, and Takeda; speaker fees from AstraZeneca, MSD, Roche, Takeda; and travel, accommodations and expenses paid by AstraZenca, BMS, Boehringer Ingelheim, Lilly, MSD, Otsuka, Roche, and Takeda. JB has declared consulting/advisory role for MSD and Astra Zeneca. PPS has declared consulting/advisory role for Sanofi and Abbvie. AP has declared consulting/advisory role for Takeda and Sanofi. MP has declared consulting/advisory role for Gilead and Bayer. AG has declared consulting/advisory role for Roche, MSD, Eli Lilly, Pierre Fabre, EISAI, and Daichii Sankyo; speaker’s bureau for Eisai, Novartis, Eli Lilly, Roche, Teva, Gentili, Pfizer, Astra Zeneca, Celgene, and Daichii Sankyo; research funds: EISAI, Eli Lilly, and Roche. LR reports receiving consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, and Sanofi; lecture fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, and Sanofi; travel fees from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, and Roche. No potential conflicts of interest were disclosed by other authors. (© The Author(s), 2021.) |
| References: | Support Care Cancer. 2020 Sep;28(9):4001-4004. (PMID: 32613372) JAMA Oncol. 2020 Oct 1;6(10):1527-1528. (PMID: 32379855) J Clin Oncol. 2010 Oct 10;28(29):4457-64. (PMID: 20837950) BMJ. 2020 Mar 26;368:m1198. (PMID: 32217618) J Pain Symptom Manage. 2020 Jul;60(1):e77-e81. (PMID: 32325167) Curr Oncol. 2018 Dec;25(6):403-408. (PMID: 30607115) Resuscitation. 2006 Nov;71(2):152-60. (PMID: 16987581) J Palliat Care. 2004 Summer;20(2):69-77. (PMID: 15332470) Cancers (Basel). 2020 Jul 08;12(7):. (PMID: 32650523) J Pain Symptom Manage. 2021 Sep;62(3):460-470. (PMID: 33556496) J Epidemiol Community Health. 2006 May;60(5):412-6. (PMID: 16614331) Ann Oncol. 2020 Jul;31(7):894-901. (PMID: 32224151) J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686) Cancer Discov. 2020 Jul 31;:. (PMID: 32737082) BMJ Support Palliat Care. 2020 Dec;10(4):381-384. (PMID: 32467101) Int J Clin Pharm. 2015 Oct;37(5):767-75. (PMID: 25854310) Head Neck. 2020 Jun;42(6):1144-1146. (PMID: 32338809) Palliat Med. 2020 Jul;34(7):889-895. (PMID: 32348711) J Clin Oncol. 2010 Mar 1;28(7):1203-8. (PMID: 20124172) J Pain Symptom Manage. 2020 Jul;60(1):e27-e30. (PMID: 32276101) Palliat Med. 2020 Oct;34(9):1193-1201. (PMID: 32706299) J Pain Symptom Manage. 2003 Feb;25(2):150-68. (PMID: 12590031) J Pain Symptom Manage. 2020 Jul;60(1):e31-e40. (PMID: 32278097) Palliat Med. 2020 Oct;34(9):1235-1240. (PMID: 32588748) Lancet Oncol. 2018 Mar;19(3):394-404. (PMID: 29402701) Palliat Med. 2020 Oct;34(9):1249-1255. (PMID: 32736493) J Pain Symptom Manage. 2014 Mar;47(3):579-587.e6. (PMID: 23972575) BMJ. 2020 Jul 14;370:m2710. (PMID: 32665316) N Engl J Med. 2010 Aug 19;363(8):733-42. (PMID: 20818875) Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) Asian J Psychiatr. 2020 Dec;54:102355. (PMID: 33271684) J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660) Palliat Med. 2008 Jan;22(1):51-7. (PMID: 18216077) Soc Sci Med. 2004 Jun;58(12):2431-44. (PMID: 15081195) JAMA. 2020 May 12;323(18):1771-1772. (PMID: 32219360) Lancet. 2020 Apr 11;395(10231):1168. (PMID: 32278369) Nat Rev Immunol. 2020 Jun;20(6):363-374. (PMID: 32346093) J Clin Oncol. 2012 Mar 10;30(8):880-7. (PMID: 22312101) J Clin Oncol. 2008 Aug 10;26(23):3860-6. (PMID: 18688053) Nat Med. 2020 Oct;26(10):1636-1643. (PMID: 32839624) |
| معلومات مُعتمدة: | 30195 United Kingdom CRUK_ Cancer Research UK |
| فهرسة مساهمة: | Keywords: COVID-19; cancer; end-of life care (EOLC); end-of-life (EOL); speciality palliative care team (SPCT) |
| تواريخ الأحداث: | Date Created: 20210909 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC8419540 |
| DOI: | 10.1177/17588359211042224 |
| PMID: | 34497669 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1758-8340 |
|---|---|
| DOI: | 10.1177/17588359211042224 |